Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Apothecary tirzepatide recall explained

FDA records show a 22-vial compounded tirzepatide recall over sterility assurance. Here is what the Class II action does and does not show.

Why we wrote this. A recall headline can make a compounded vial sound interchangeable with Zepbound. The FDA record supports a narrower, product-specific account.

In this article (6 sections)
  1. What the FDA record says
  2. What Class II means
  3. Compounded tirzepatide is not Zepbound
  4. What patients can verify
  5. What we do not yet know
  6. Medical disclaimer

Apothecary Pharma recalled 22 vials of compounded tirzepatide after the firm could not assure sterility. The FDA record identifies one 18 mg/mL multidose-vial product, distributed nationwide in the United States, and classifies the recall as Class II[1]. This is a product-quality action, not a clinical trial result and not a recall of Eli Lilly's Zepbound.

What the FDA record says

Apothecary Pharma initiated the voluntary recall on September 24, 2026. The FDA classified it on October 8 and reported it on October 14. The agency lists the reason as lack of assurance of sterility. The affected product is described as tirzepatide injection, 18 mg/mL, in a 4 mL sterile multidose vial. Its recall number is D-0036-2027[1].

The recall record names 22 lot numbers, AP-202622 through AP-202644 with one number absent from the sequence. Their beyond-use dates run from October 7 through November 26, 2026. The record says distribution was nationwide and the recall remained ongoing when the dataset was last updated. A separate NAD+ vial appears under the same event ID, so readers should not treat every product in the event as tirzepatide.

What Class II means

BioPharma Dive reported that FDA assigned a Class II classification, the category used when exposure may cause temporary or medically reversible harm, or when serious harm is considered remote[2]. Classification describes the assessed health-risk level. It does not prove that every recalled vial was contaminated or that a patient was injured.

Sterility is still a central issue for an injectable product. A multidose vial is entered more than once, and a sterility failure could introduce microorganisms into tissue or the bloodstream. The public record does not provide patient case reports, laboratory findings for each lot, or a count of adverse events. Those gaps limit what can be concluded beyond the recall itself.

Compounded tirzepatide is not Zepbound

Zepbound is an FDA-approved tirzepatide product with a prescribing label, specified presentations, manufacturing controls, and postmarket reporting obligations. DailyMed identifies Zepbound as a prescription tirzepatide injection supplied by Eli Lilly[3]. Apothecary's 18 mg/mL multidose vial is a different product from a different firm. Calling it a copycat may explain the commercial relationship, but it should not blur that regulatory distinction.

Compounding can serve an individual patient need, but compounded drugs do not go through FDA premarket review for safety, effectiveness, and manufacturing quality in the same way as approved medicines. The FDA recall concerns this named product and these named lots. It does not establish that all compounded tirzepatide is contaminated, and it does not change the evidence behind approved tirzepatide uses and regulation.

What patients can verify

A patient with a vial from Apothecary Pharma can compare the firm name, concentration, vial size, lot number, and beyond-use date with the FDA record. Anyone who may have used an affected product should contact the dispensing pharmacy and their clinician for case-specific advice. Symptoms after an injection, especially fever, worsening redness, swelling, drainage, severe pain, or feeling acutely unwell, warrant prompt medical assessment.

The recall entry does not instruct readers to change a dose or substitute another product on their own. It also does not answer whether a particular vial was used correctly or remained sterile after first puncture. Those are separate questions for the pharmacy and treating clinician.

The concentration deserves attention when identifying the product. The recalled vial is listed at 18 mg/mL in a 4 mL container. A familiar drug name alone is not enough to match a prescription or vial to a recall. Patients should use the complete label rather than comparing appearance, cap color, or an online product photo. Pharmacists can also check dispensing records when a vial is no longer available.

FDA's quantity field and its lot list describe different things. The entry reports 22 vials in total and also supplies 22 lot numbers. That unusual one-vial-per-lot pattern comes directly from the agency dataset. It should not be rewritten as 22 vials in each lot or as thousands of doses. The record gives no basis for either claim.

A recall also differs from a market-wide withdrawal. This action identifies a firm, a product description, and specific lot codes. It does not remove tirzepatide as a molecule from approved use, invalidate results from tirzepatide trials, or announce a new adverse effect of the active ingredient. The trigger concerns whether the compounded injectable product's sterility could be assured.

What we do not yet know

The public FDA dataset does not state what inspection, test, or process failure led to the lack-of-sterility assurance. It does not report how many of the 22 vials reached patients, whether any were returned, or whether cultures found a specific organism. BioPharma Dive adds industry and legal context, but it cannot fill those product-level evidence gaps.

Future FDA updates may change the recall status or add details. Until then, the narrow finding is the defensible one: one compounder voluntarily recalled one 22-vial tirzepatide product run because sterility could not be assured.

Medical disclaimer

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Was Zepbound recalled?

No. The FDA record names an Apothecary Pharma compounded tirzepatide product. It does not name Eli Lilly's FDA-approved Zepbound product.

Which compounded tirzepatide lots were recalled?

The FDA record lists 22 lots, with beyond-use dates from October 7 through November 26, 2026. Patients should compare the complete lot and product details in the FDA record with their vial and contact the dispensing pharmacy.

Does a Class II recall mean contamination was confirmed?

No. The stated reason is lack of assurance of sterility. The public record does not say that every vial was contaminated or report a microorganism. Class II describes the assessed risk category.

Sources

  1. [1]openFDA drug enforcement record for event 99952Tier 1 · primary↩
  2. [2]BioPharma Dive: GLP-1 compounder issues recall for copycat ZepboundTier 2 · expert↩
  3. [3]DailyMed: Zepbound tirzepatide prescribing informationTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars